5) Ad26+MVA therapeutic vaccine in early-treated individuals: https://t.co/nlGe69ESFm 6) bNAbs boost T cell immunity: https://t.co/tgxYVUb7O5 7) NHP study of bNAbs as PrEP: https://t.co/sYU4lvjLhn
Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity. https://t.co/DEvWLJBakg
RT @BcnVih: #PapersOnFire 📄🌍con la Dra. @NuriaCliment1 ¿Más cerca del control del #VIH a largo plazo? Niessl et al publican en @NatureMedi…
RT @BcnVih: #PapersOnFire 📄🌍con la Dra. @NuriaCliment1 ¿Más cerca del control del #VIH a largo plazo? Niessl et al publican en @NatureMedi…
RT @BcnVih: #PapersOnFire 📄🌍con la Dra. @NuriaCliment1 ¿Más cerca del control del #VIH a largo plazo? Niessl et al publican en @NatureMedi…
RT @BcnVih: #PapersOnFire 📄🌍con la Dra. @NuriaCliment1 ¿Más cerca del control del #VIH a largo plazo? Niessl et al publican en @NatureMedi…
#PapersOnFire 📄🌍con la Dra. @NuriaCliment1 ¿Más cerca del control del #VIH a largo plazo? Niessl et al publican en @NatureMedicine que la terapia combinada de #anticuerpos #antiVIH1 promueve una mayor inmunidad de #célulasT específicas frente al virus🔗htt
#ActualidadCientífica Un nuevo estudio publicado en la revista @NatureMedicine presenta la inmunoterapia como posible nueva estrategia terapéutica contra el #VIH https://t.co/00XXRfbopQ
Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity https://t.co/o5JTNN2qdO
RT @NatureMedicine: T cell responses specific for HIV-1 Gag peptides increased in HIV-positive recipients of two broadly neutralizing antib…
#HIV #antibody #therapy is associated with enhanced immune responses in infected individuals: https://t.co/O9UeG7TwTy https://t.co/xlwQF87UK8
RT @lamethodeFC: @iciradiocanada [L’étude à découvrir] 03/02 > La combinaison d'anticorps anti-VIH-1 est associée à une immunité accrue aux…
@iciradiocanada [L’étude à découvrir] 03/02 > La combinaison d'anticorps anti-VIH-1 est associée à une immunité accrue aux lymphocytes T spécifiques au virus https://t.co/qPulVUOpqJ via @NatureMedicine #LaMethSci
Just got around to reading this - really exciting work that raises a lot of important questions about the immune mechanisms underlying bNAb treatment for HIV https://t.co/WdGiGjntob
RT @NatureMedicine: T cell responses specific for HIV-1 Gag peptides increased in HIV-positive recipients of two broadly neutralizing antib…
Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity | Nature Medicine https://t.co/FnO6hLEq1o
Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity. https://t.co/yztT5lGGS4
RT @HIVEnterprise: Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity. https://t.co/xy9lAD…
RT @HIVEnterprise: Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity. https://t.co/xy9lAD…
Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity. https://t.co/xy9lAD9JzH
Amazing work by my colleagues D. Kaufmann and his team On #HIV antibody therapy. @crchum #Immunopathology division
RT @pilar_daroca: #bNAb treatment correlates with an increased #HIV-specific CD8+ response. It’s been great collaborating with Daniel Kaufm…
RT @defeatHIV: bNAb therapy during ART interruption is associated with enhanced HIV-specific T cell responses. Whether these augmented T c…
RT @NatureMedicine: T cell responses specific for HIV-1 Gag peptides increased in HIV-positive recipients of two broadly neutralizing antib…
RT @pilar_daroca: #bNAb treatment correlates with an increased #HIV-specific CD8+ response. It’s been great collaborating with Daniel Kaufm…
RT @NatureMedicine: T cell responses specific for HIV-1 Gag peptides increased in HIV-positive recipients of two broadly neutralizing antib…
RT @pilar_daroca: #bNAb treatment correlates with an increased #HIV-specific CD8+ response. It’s been great collaborating with Daniel Kaufm…
RT @pilar_daroca: #bNAb treatment correlates with an increased #HIV-specific CD8+ response. It’s been great collaborating with Daniel Kaufm…
RT @defeatHIV: bNAb therapy during ART interruption is associated with enhanced HIV-specific T cell responses. Whether these augmented T c…
#bNAb treatment correlates with an increased #HIV-specific CD8+ response. It’s been great collaborating with Daniel Kaufmann and Julia Nießl on this project! Congratulations for all the hard work!! https://t.co/5PFc83JsLL
RT @NatureMedicine: T cell responses specific for HIV-1 Gag peptides increased in HIV-positive recipients of two broadly neutralizing antib…
RT @defeatHIV: bNAb therapy during ART interruption is associated with enhanced HIV-specific T cell responses. Whether these augmented T c…
RT @defeatHIV: bNAb therapy during ART interruption is associated with enhanced HIV-specific T cell responses. Whether these augmented T c…
RT @defeatHIV: bNAb therapy during ART interruption is associated with enhanced HIV-specific T cell responses. Whether these augmented T c…
bNAb therapy during ART interruption is associated with enhanced HIV-specific T cell responses. Whether these augmented T cell responses can contribute to bNAb-mediated #HIV control remains to be determined. https://t.co/1vl3elV4y6 #hivcure https://t.co
RT @NatureMedicine: T cell responses specific for HIV-1 Gag peptides increased in HIV-positive recipients of two broadly neutralizing antib…
Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity «These data demonstrate that bNAb therapy during ART interruption is associated with enhanced HIV-1-specific T cell responses.» https://t.co/mF0mThtCqR
Nice study from Daniel Kaufmann and Michel Nussenzweig' s lab!
RT @NatureMedicine: T cell responses specific for HIV-1 Gag peptides increased in HIV-positive recipients of two broadly neutralizing antib…
Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity https://t.co/OhtJqFRJx3 https://t.co/bUUE52ckty
RT @NatureMedicine: T cell responses specific for HIV-1 Gag peptides increased in HIV-positive recipients of two broadly neutralizing antib…
T cell responses specific for HIV-1 Gag peptides increased in HIV-positive recipients of two broadly neutralizing antibodies with prolonged suppression of blood viremia during antiretroviral treatment interruption #HIV #antibodies @RockefellerUniv @CRCHUM
#NatureMedicine Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity https://t.co/4ZM4wXkIyL
HIV antibody #therapy associated with enhanced #immune responses in people living with #HIV. Study @NatureMedicine led by @CRCHUM and @RockefellerUniv researchers. @NIH @CIHR_IRSC @FRQS1 > New : https://t.co/VPi0yLicW3 > Study : https://t.co/8b7Tz0oG